Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

VBP

- PMLiVE

NICE set to reject Kyowa Kirin’s Crysvita for XLH

Committee says the rare disease therapy isn’t value for money

- PMLiVE

Daily Brief: Keytruda and microbiome synergy, Pfizer’s files PARP contender and more

Your daily injection of pharma news

- PMLiVE

Daily Brief:  NICE says no to Zytiga, Genentech and UK biotech sign microbiome deal

All the latest from the frontlines of healthcare

- PMLiVE

Keytruda cleared for frontline lung cancer in England – but only after another pricing deal

Keytruda first drug to exit Cancer Drugs Fund and go through Budget Impact Test

- PMLiVE

Daily Brief: BIO takes over from ASCO, Greece’s Novartis bribery case and more

Highlights from the world of pharma, biotech and healthcare

- PMLiVE

NICE backs Tesaro’s Zejula via the CDF

Recommends the drug for second-line use in ovarian cancer patients

- PMLiVE

Patient outcomes in practice: delivering value that transforms lives

Over the next five years, the NHS needs to drive efficiencies of £22bn. Like all global healthcare systems, it faces the challenge of improving the health of larger and older...

Improving NHS sustainability through service redesign partnerships and effective communications

With year-on-year increases in demand and the imperative to reduce its deficits, the NHS must look beyond merely doing more of the same if it is to become sustainable. Never...

- PMLiVE

Improving childhood cancer survival rates in developing countries

IntroductionOne of the remarkable success stories in cancer care has been the increase in the long-term survival of children with leukaemia and solid tumours from almost nil to 75-80% cure...

NHS collaborates with VisualDX

CCGs will now have access to diagnostic clinical decision support resource

The NHS and ABPI at 70: inching closer to the triple win

The NHS and UK pharma’s ABPI both turn 70 this year. After years of transactional relationships, there’s a will to work more closely - but friction on prices and value...

- PMLiVE

Daily Brief: Azar blasts pharma, NICE forces MS drug prices down, Xenicos gets $30m funding

News from the frontline of healthcare, pharma and biotech

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links